PSNL shares should trade near the $16.25 deal price with a small spread reflecting closing risk (shareholder vote, regulatory approvals, and the Tempus stock price floor of $46.00). Monitor for any competing bids, regulatory hurdles, or shareholder dissent. TEM shares may face modest dilution overhang given the stock consideration structure.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 20 $13.34entry
- T+1 · 4mo ago +0.75%α −0.08% · $13.44
- T+5 · 4mo ago −11.69%α −11.27% · $11.78
- T+20 · 3mo ago +4.12%α +0.00% · $13.89
- T+60 · 5w ago +18.82%α +13.98% · $15.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tempus AI (TEM) announced a definitive agreement to acquire Personalis (PSNL) for $16.25 per share in a stock transaction valued at $1.5 billion enterprise value, representing a 6% premium to the prior close and a 28% premium to the 30-day VWAP. The deal combines Personalis' MRD technology with Tempus' AI platform and commercial infrastructure, with closing expected in late 2026 or early 2027. Personalis also reported preliminary Q2 revenue of $22.4 million and 10,384 clinical tests, a 33% sequential volume increase.
Key Financial Metrics
Key Facts
- Tempus to acquire Personalis for $16.25 per share, total enterprise value of $1.5 billion
- Consideration is 100% stock with Tempus option to elect cash up to 50%
- Premium of 6% to Friday's close and 28% to 30-day VWAP
- Personalis reported preliminary Q2 revenue of $22.4 million and 10,384 clinical tests (+33% QoQ)
- Closing expected late 2026 or early 2027, subject to shareholder and regulatory approvals
- Transaction approved by both boards; Personalis conducted an 'exhaustive process'
- MRD market described as a $20 billion opportunity
Financial Impact
$1.5 billion enterprise value acquisition at $16.25/share; Personalis Q2 preliminary revenue $22.4M
Risk Factors
- Personalis shareholders may not approve the merger
- Regulatory approvals may be delayed or impose conditions
- Tempus stock price falling below $46.00 gives Personalis termination right
- Integration risks and potential failure to achieve synergies
- Potential litigation related to the transaction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-308500 |
| Document: 0001193125-26-308500-index-headers.html | 0001193125-26-308500 |
| Document: 0001193125-26-308500-index.html | 0001193125-26-308500 |
| Document: 0001193125-26-308500.txt | 0001193125-26-308500 |
Track record
29 reports on PSNL
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +18.82% at T+60 after the Jul 20, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.16 Now $14.80 −2.34% settles Feb 12
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $15.71 Now $14.80 −5.79% settles Feb 11
- Nov 12, 20264d ago 425 Neutral 4/10 Entry $15.86 Now $14.80 −6.68% settles Feb 10
- Nov 6, 202610d ago 425 Neutral 3/10 Entry $15.95 Now $14.80 −7.21% settles Feb 5
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $15.55 Now $14.80 −4.82% settles Feb 3
- Nov 3, 202613d ago 425 Neutral 3/10 Entry $15.79 Now $14.80 −6.27% settles Feb 2
- Oct 30, 202617d ago 425 Neutral 4/10 Entry $15.76 Now $14.80 −6.09% settles Jan 29
- Oct 21, 202626d ago DEFM14A Neutral 5/10 Entry $15.82 Now $14.80 −6.45% settles Jan 20
- Oct 20, 202627d ago 425 Neutral 4/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
- Oct 20, 202627d ago 425 Neutral 5/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers